Recombinant Fusion Proteins

DBCAT002953Pharmacologic class

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. A DrugBank category of 8 drugs. 6 of them are approved.

Also known as: Chimeric Proteins, Recombinant · Fusion Proteins, Recombinant · Hybrid Proteins, Recombinant · Proteins, Recombinant Chimeric · Proteins, Recombinant Fusion
Drugs: Alefacept
Atacicept
Denileukin diftitox
Efanesoctocog alfa
PRO-542
rGLP-1
Sotatercept
Tagraxofusp

What you can answer from here — as of November 01, 2016

8DrugsEach linked to its full drug card

Listed above

21Drug targetsEvery drug–target pair in the class, with bond type

39Marketed productsAcross the regions we cover, with dosage forms and routes

4Routes of administrationHow the drugs in this class are given

Which targets do Recombinant Fusion Proteins share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account